. . "investigational"@en . " "@en . "884604-91-5"@en . "Imiglucerase"@en . . "# Pastores GM: Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease. Curr Opin Investig Drugs. 2010 Apr;11(4):472-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20336596 # Vairo F, Netto C, Dorneles A, Mittelstadt S, Wilke M, Doneda D, Michelin K, Ribeiro CB, Quevedo A, Vieira T, Nalin T, Lueska S, Schwartz IV: Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment. JIMD Rep. 2013 Feb 21. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/23430813"@en . . . . . "approved"@en . "VPRIV"@en . . . . "Velaglucerase alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease."@en . . "Velaglucerase alfa catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside."@en . . . . "Velaglucerase alfa"@en . "11-12 minutes. "@en . . "Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease. "@en . "Mean clearance ranges from 6.72 to 7.56 mL/min/kg."@en . "The mean volume of distribution at steady state ranges from 82 to 108 mL/kg (8.2% to 10.8% of body weight)."@en . .